US-listed shares of Zai Lab slide after commencing $200 mln stock offering
** U.S.-listed shares of China-based drug developer Zai Lab
ZLAB.O fall 6% to $28.11 after the bell
** ZLAB commences public offering of $200 mln of American
depositary shares
** Company plans to use the proceeds for general corporate
purposes
** ZLAB has 98 mln outstanding shares, with a capitalization
of $3 bln market, according to data compiled by LSEG
** Goldman Sachs, Jefferies and Leerink Partners are the
joint book-running managers for the offering
** As of last close, ZLAB shares up 9.6% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows